The therapeutic role of glucagon-like peptide-1 agonists and sodium-glucose cotransporter-2 inhibitors in the management of lean NAFLD is not fully defined and requires further investigation. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.